Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo

Venkata R. Krishnamurthy; Mohammed Y R Sardar; Yu Ying; Xuezheng Song; Carolyn Haller; Erbin Dai; Xiaocong Wang; Donny Hanjaya-Putra; Lijun Sun; Vasilios Morikis; Scott I. Simon; Robert J. Woods; Richard D. Cummings; Elliot L. Chaikof

doi:10.1038/ncomms7387

Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo

Venkata R. Krishnamurthy, Mohammed Y R Sardar, Yu Ying, Xuezheng Song, Carolyn Haller, Erbin Dai, Xiaocong Wang, Donny Hanjaya-Putra, Lijun Sun, Vasilios Morikis, Scott I. Simon, Robert J. Woods, Richard D. Cummings, Elliot L. Chaikof

Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Blockade of P-selectin (P-sel)/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogues. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-sel with nanomolar affinity (K d ∼22nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-sel/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.

Original language	English (US)
Article number	6387
Journal	Nature Communications
Volume	6
DOIs	https://doi.org/10.1038/ncomms7387
State	Published - Mar 31 2015

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Chemistry(all)
Physics and Astronomy(all)

Access to Document

10.1038/ncomms7387

Cite this

Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. / Krishnamurthy, Venkata R.; Sardar, Mohammed Y R; Ying, Yu; Song, Xuezheng; Haller, Carolyn; Dai, Erbin; Wang, Xiaocong; Hanjaya-Putra, Donny; Sun, Lijun; Morikis, Vasilios; Simon, Scott I.; Woods, Robert J.; Cummings, Richard D.; Chaikof, Elliot L.

In: Nature Communications, Vol. 6, 6387, 31.03.2015.

Research output: Contribution to journal › Article › peer-review

Krishnamurthy, Venkata R. ; Sardar, Mohammed Y R ; Ying, Yu ; Song, Xuezheng ; Haller, Carolyn ; Dai, Erbin ; Wang, Xiaocong ; Hanjaya-Putra, Donny ; Sun, Lijun ; Morikis, Vasilios ; Simon, Scott I. ; Woods, Robert J. ; Cummings, Richard D. ; Chaikof, Elliot L. / Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. In: Nature Communications. 2015 ; Vol. 6.

@article{5f37144e9d8b4ebc89477ee22457987f,

title = "Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo",

abstract = "Blockade of P-selectin (P-sel)/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogues. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-sel with nanomolar affinity (K d ∼22nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-sel/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.",

author = "Krishnamurthy, {Venkata R.} and Sardar, {Mohammed Y R} and Yu Ying and Xuezheng Song and Carolyn Haller and Erbin Dai and Xiaocong Wang and Donny Hanjaya-Putra and Lijun Sun and Vasilios Morikis and Simon, {Scott I.} and Woods, {Robert J.} and Cummings, {Richard D.} and Chaikof, {Elliot L.}",

year = "2015",

month = mar,

day = "31",

doi = "10.1038/ncomms7387",

language = "English (US)",

volume = "6",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo

AU - Krishnamurthy, Venkata R.

AU - Sardar, Mohammed Y R

AU - Ying, Yu

AU - Song, Xuezheng

AU - Haller, Carolyn

AU - Dai, Erbin

AU - Wang, Xiaocong

AU - Hanjaya-Putra, Donny

AU - Sun, Lijun

AU - Morikis, Vasilios

AU - Simon, Scott I.

AU - Woods, Robert J.

AU - Cummings, Richard D.

AU - Chaikof, Elliot L.

PY - 2015/3/31

Y1 - 2015/3/31

N2 - Blockade of P-selectin (P-sel)/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogues. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-sel with nanomolar affinity (K d ∼22nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-sel/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.

AB - Blockade of P-selectin (P-sel)/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogues. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-sel with nanomolar affinity (K d ∼22nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-sel/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84926307673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926307673&partnerID=8YFLogxK

U2 - 10.1038/ncomms7387

DO - 10.1038/ncomms7387

M3 - Article

AN - SCOPUS:84926307673

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 6387

ER -

Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this